Funding format: ProFIT („Programm zur Förderung der Forschung, Innovationen und Technologien“)

Project partners:

  • Fraunhofer Institute for Cell Therapy and Immunology, Branch Bioanalytics and Bioprocesses, Potsdam-Golm (IZI-BB),
    Department of Cell-free and Cell-based Bioproduction / Cell-free Protein Synthesis
  • YUMAB GmbH


  • Generation of monoclonal antibodies (mAbs) targeting combined epitopes comprising tumor-related proteins and their tumor-specific glycosylation
  • Generation of monoclonal IgG1 antibodies by phage-display technology incl. human antibody libraries using different antigens and reference materials
  • Antibody screening, identification of lead candidates and format optimization (bispecifics, immunocytokines and antibody-drug-conjugates) for improved efficacy by use of cell-free and cellular production technologies

Expected results:

  • Identification of optimal work-flows for antigen generation with subsequent phage-display / panning for selection of antibodies
  • Generation of new antibodies targeting O-glycopeptide mixed epitopes with the following advantages:
Characteristics Protein-specific mAb Glycan-specific mAb Glyco-protein (mix) epitope-specific mAb
High tumor specificity X
High number of binding sites per cell X
High affinity X
Signaling function X
Impact on tumor progression
Expression on tumor stem cells
  • New lead candidates combining high binding affinity and tumor specificity for improved safety as well as high anti-tumor efficacy available for further development in oncology